Crinetics Pharmaceuticals... (CRNX)
NASDAQ: CRNX
· Real-Time Price · USD
31.07
-0.70 (-2.20%)
At close: Jun 16, 2025, 3:59 PM
31.50
1.38%
After-hours: Jun 16, 2025, 05:24 PM EDT
-2.20% (1D)
| Bid | 30 |
| Market Cap | 2.91B |
| Revenue (ttm) | 760K |
| Net Income (ttm) | -328.25M |
| EPS (ttm) | -3.8 |
| PE Ratio (ttm) | -8.18 |
| Forward PE | -6.86 |
| Analyst | Buy |
| Ask | 32.5 |
| Volume | 376,304 |
| Avg. Volume (20D) | 945,357 |
| Open | 32.00 |
| Previous Close | 31.77 |
| Day's Range | 30.96 - 31.77 |
| 52-Week Range | 24.10 - 62.53 |
| Beta | 0.28 |
About CRNX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CRNX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CRNX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts7 months ago
+1.26%
Crinetics Pharmaceuticals shares are trading highe...
Unlock content with
Pro Subscription
10 months ago
-6.11%
Crinetics Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q2 financial results. Additionally, the company announced its CFO will be departing and Oppenheimer lowered its price target on the stock from $74 to $73.
1 month ago · seekingalpha.com
Crinetics Pharmaceuticals, Inc (CRNX) Q1 2025 Earnings Call TranscriptCrinetics Pharmaceuticals, Inc (NASDAQ:CRNX ) Q1 2025 Results Conference Call May 8, 2025 4:30 PM ET Company Participants Gayathri Diwakar - Head-Investor Relations Scott Struthers - Founder and Chief...
2 months ago · seekingalpha.com
Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFACrinetics Pharma's lead asset, Paltusotine, shows promising Phase 3 results for acromegaly, with a PDUFA date set for September 25, 2024. Paltusotine, an oral SST2 agonist, offers advantages over inje...